演題詳細

ポスター / Poster

ポスター 12 (Poster 12) :MDS:臨床 1

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
波多 智子 (Tomoko Hata):1
1:長崎大学原爆後障害医療研究所 血液内科学研究分野(原研内科)
 
前へ戻る

Long-term cytogenetic response in a Japanese del(5q) MDS patient treated with low-dose lenalidomide

演題番号 : PS-1-88

金子 雅紀 (Masanori Kaneko):1、宮崎 浩二 (Koji Miyazaki):1、赤川 直之 (Naoyuki Akagawa):1、木村 明華 (Sayaka Kimura):1、木村 裕和 (Hirokazu Kimura):1、栂野 富輝 (Tomiteru Togano):1、檀原 幹生 (Mikio Danbara):1、堀江 良一 (Ryouichi Horie):1、東原 正明 (Masaaki Higashihara):1

1:Department of Hematology, Kitasato University School of Medicine

 

Lenalidomide is manifested with high rates of erythoroid and cytogenetic responses in del(5q) MDS patients. However, long-term follow-up data have been limited especially in the Japanese population. We herein report a rare case, who has maintained cytogenetic remission for more than 2.5 years with a reduced dose of lenalidomide treatment. The case was a 71 year-old Japanese female with transfusion-independent anemia (Hb 9.3g/dL). Lenalidomide was initiated at a dose of 5mg daily for 21 days of every 28-day cycle. Anemia was ameliorated within a month and achieved complete cytogenetic response in eight months of initiating treatment, and has maintained remission thereafter. Adverse events were minimal. In the previous Japanese study (MDS007) 10mg lenalidomide was administered to eleven patients daily for 21 days of every 28-day cycle. High rates of erythroid and even cytogenetic responses were obtained, and 5q abnormality was undetectable by interphase FISH only in two patients. In eight out of eleven patients a dose-reduction was required from 10mg to 5mg daily because of adverse events. Management of adverse events with appropriate drug dose adjustment could optimize patient tolerance and the potential to maintain long-term response. This case implies that low dose treatment of lenalidomide might be enough especially for some Japanese patients. We have still never known an optimal dosage for Japanese patients and predictive factors to identify those who benefit from lenalidomide. In order to address these unresolved questions, an accumulation of cases is required.

前へ戻る